Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 8, 2023
[ Thu, Jun 08th 2023
] - WOPRAI
[ Thu, Jun 08th 2023
] - WOPRAI
[ Thu, Jun 08th 2023
] - WOPRAI
[ Thu, Jun 08th 2023
] - WOPRAI
[ Thu, Jun 08th 2023
] - WOPRAI
[ Thu, Jun 08th 2023
] - WOPRAI
[ Thu, Jun 08th 2023
] - WOPRAI
[ Thu, Jun 08th 2023
] - WOPRAI
Wed, June 7, 2023
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
[ Wed, Jun 07th 2023
] - WOPRAI
Edward Tenthoff Maintained (APTO) at Buy with Decreased Target to $37 on, Jun 7th, 2023
Edward Tenthoff of Piper Sandler, Maintained "Aptose Biosciences Inc." (APTO) at Buy with Decreased Target from $45 to $37 on, Jun 7th, 2023.
Edward has made no other calls on APTO in the last 4 months.
There are 3 other peers that have a rating on APTO. Out of the 3 peers that are also analyzing APTO, 0 agree with Edward's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Edward
- Joseph Pantginis of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $180 on, Tuesday, May 9th, 2023
- Matthew Biegler of "Oppenheimer" Reiterated at Buy and Held Target at $135 on, Tuesday, May 9th, 2023
- Carey Macrury of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $120 on, Monday, March 27th, 2023
